We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Despite progress on a flu jab, the biotech group will be lossmaking for the next three years
Trial finds latest version elicited better immune response than existing jabs
Drug regulator’s decision is the first step towards a new round of jabs as cases rise in the US
Prominent figure in UK pandemic response becomes medical consultant at pharma group
Medicines produced by pharma group will be for domestic use only
Noubar Afeyan says court rulings on abortion pills and access to healthcare undermine efforts to combat diseases
Covid vaccine maker is sitting on $18bn and embarking on a host of ambitious projects
Four member states including Poland say amended deal is not ‘fair solution’ to surplus of shots
Success in battle against Covid does not ensure success against tumours, but should narrow the odds
Study suggests combination with Merck immunotherapy drug reduces risk of death in high-risk patients
Ending of pharma group’s IP truce spells fight for future of mRNA technology
Jab maker ties weaker revenue outlook to delivery delays and manufacturing issues
Pharmaceutical companies hunt for new revenue streams as coronavirus becomes endemic
Chinese biotech’s research chief calls decision ‘unfortunate’ as zero-Covid policy strangles economy
Pharma company still ‘eager’ to collaborate with Beijing, despite collapse of initial talks
Experts are concerned that the US isn’t doing enough to support the development of the next wave of vaccines and treatments that the world needs to fight the Covid-19 pandemic
FDA clears jabs despite lack of human trials in effort to curb winter wave of Covid infections
US biotech claims rival Covid vaccine makers infringed patents underpinning jabs developed to combat the pandemic
Moderna’s two-strain shot will target both the original strain and BA.1 in step with European regulators
The chair of the $60bn US biopharma group explains how his approach to combining science with entrepreneurship led to the company’s creation
US biotech group says shot targeting both first strain and Omicron could help avert ‘large rise’ in cases
Government seeks to secure domestic jab supply and prepare for future pandemics in deal with Boston biotech
US prepares to roll out jabs to last age group without access once regulatory approval is received
US pharma company aims to roll out the new vaccine by late summer
International Edition
